Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 107

1.

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.

Fountzilas G, Giannoulatou E, Alexopoulou Z, Zagouri F, Timotheadou E, Papadopoulou K, Lakis S, Bobos M, Poulios C, Sotiropoulou M, Lyberopoulou A, Gogas H, Pentheroudakis G, Pectasides D, Koutras A, Christodoulou C, Papandreou C, Samantas E, Papakostas P, Kosmidis P, Bafaloukos D, Karanikiotis C, Dimopoulos MA, Kotoula V.

Oncotarget. 2016 Apr 26. doi: 10.18632/oncotarget.9022. [Epub ahead of print]

2.

Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.

Lakis S, Dimoudis S, Kotoula V, Alexopoulou Z, Kostopoulos I, Koletsa T, Bobos M, Timotheadou E, Papaspirou I, Efstratiou I, Aravantinos G, Karavasilis V, Zagouri F, Gogas H, Razis E, Pentheroudakis G, Christodoulou C, Pectasides D, Fountzilas G.

Anticancer Res. 2016 May;36(5):2365-78.

PMID:
27127145
3.

Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.

Purrington KS, Visscher DW, Wang C, Yannoukakos D, Hamann U, Nevanlinna H, Cox A, Giles GG, Eckel-Passow JE, Lakis S, Kotoula V, Fountzilas G, Kabisch M, Rüdiger T, Heikkilä P, Blomqvist C, Cross SS, Southey MC, Olson JE, Gilbert J, Deming-Halverson S, Kosma VM, Clarke C, Scott R, Jones JL, Zheng W, Mannermaa A; Jane Carpenter for ABCTC Investigators, Eccles DM, Vachon CM, Couch FJ.

Breast Cancer Res Treat. 2016 Apr 15. [Epub ahead of print]

PMID:
27083182
4.

Tubular Pyloric Gland Adenoma of the Left and Right Hepatic Ducts: Report of a Unique Case With Immunohistochemical and Molecular Studies.

Hatzibougias DI, Fouzas I, Bobos M, Papanikolaou V, Daoudaki M, Kotoula V, Hytiroglou P, Albores-Saavedra J.

Int J Surg Pathol. 2016 Jan 13. pii: 1066896915625110. [Epub ahead of print]

PMID:
26762143
5.

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.

Cohen SA, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, Grady WM.

Clin Colorectal Cancer. 2015 Nov 11. pii: S1533-0028(15)00144-9. doi: 10.1016/j.clcc.2015.10.005. [Epub ahead of print]

PMID:
26702772
6.

Expression pattern of the Hedgehog signaling pathway in pituitary adenomas.

Yavropoulou MP, Maladaki A, Topouridou K, Kotoula V, Poulios C, Daskalaki E, Foroglou N, Karkavelas G, Yovos JG.

Neurosci Lett. 2016 Jan 12;611:94-100. doi: 10.1016/j.neulet.2015.10.076. Epub 2015 Nov 24.

PMID:
26620835
7.

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.

Kotoula V, Chatzopoulos K, Lakis S, Alexopoulou Z, Timotheadou E, Zagouri F, Pentheroudakis G, Gogas H, Galani E, Efstratiou I, Zaramboukas T, Koutras A, Aravantinos G, Samantas E, Psyrri A, Kourea H, Bobos M, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G.

Oncotarget. 2016 Jan 26;7(4):5074-87. doi: 10.18632/oncotarget.6231.

8.

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.

Papaxoinis G, Kotoula V, Alexopoulou Z, Kalogeras KT, Zagouri F, Timotheadou E, Gogas H, Pentheroudakis G, Christodoulou C, Koutras A, Bafaloukos D, Aravantinos G, Papakostas P, Charalambous E, Papadopoulou K, Varthalitis I, Efstratiou I, Zaramboukas T, Patsea H, Scopa CD, Skondra M, Kosmidis P, Pectasides D, Fountzilas G.

PLoS One. 2015 Oct 9;10(10):e0140293. doi: 10.1371/journal.pone.0140293. eCollection 2015.

9.

Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.

Vassilakopoulou M, Avgeris M, Velcheti V, Kotoula V, Rampias T, Chatzopoulos K, Perisanidis C, Kontos CK, Giotakis AI, Scorilas A, Rimm D, Sasaki C, Fountzilas G, Psyrri A.

Clin Cancer Res. 2016 Feb 1;22(3):704-13. doi: 10.1158/1078-0432.CCR-15-1543. Epub 2015 Sep 25.

PMID:
26408403
10.

Perceptual distortions and delusional thinking following ketamine administration are related to increased pharmacological MRI signal changes in the parietal lobe.

Stone J, Kotoula V, Dietrich C, De Simoni S, Krystal JH, Mehta MA.

J Psychopharmacol. 2015 Sep;29(9):1025-8. doi: 10.1177/0269881115592337. Epub 2015 Jul 6.

PMID:
26152321
11.

Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA.

Kotoula V, Lyberopoulou A, Papadopoulou K, Charalambous E, Alexopoulou Z, Gakou C, Lakis S, Tsolaki E, Lilakos K, Fountzilas G.

PLoS One. 2015 Jun 3;10(6):e0128818. doi: 10.1371/journal.pone.0128818. eCollection 2015.

12.

Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL.

J Natl Cancer Inst. 2015 May 19;107(8). pii: djv136. doi: 10.1093/jnci/djv136. Print 2015 Aug.

PMID:
25991002
13.

Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.

Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, Syrigos KN, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G.

PLoS One. 2015 May 13;10(5):e0124612. doi: 10.1371/journal.pone.0124612. eCollection 2015.

14.

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.

Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, Vrettou E, Sgouros J, Samantas E, Basdanis G, Papakostas P, Bafaloukos D, Kotoula V, Kalofonos HP, Scopa CD, Pentheroudakis G, Fountzilas G.

BMC Cancer. 2015 May 10;15:384. doi: 10.1186/s12885-015-1406-7.

15.

Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.

Kourea HP, Kotoula V, Koutras A, Alexopoulou Z, Papaspirou I, Skarlos DV, Efstratiou I, Bobos M, Zagouri F, Papakostas P, Pectasides D, Chrisafi S, Varthalitis I, Aravantinos G, Kosmidis P, Bafaloukos D, Scopa CD, Fountzilas G.

Histol Histopathol. 2015 Sep;30(9):1129-41. doi: 10.14670/HH-11-612. Epub 2015 Mar 25.

PMID:
25807307
16.

Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.

Koutras A, Kotoula V, Fountzilas G.

Pharmacogenomics. 2015 Jan;16(1):79-94. doi: 10.2217/pgs.14.148. Review.

PMID:
25560472
17.

Protein and mRNA expression of notch pathway components in operable tumors of patients with laryngeal cancer.

Krikelis D, Kotoula V, Bobos M, Fountzilas E, Markou K, Karasmanis I, Angouridakis N, Vlachtsis K, Kalogeras KT, Nikolaou A, Fountzilas G.

Anticancer Res. 2014 Nov;34(11):6495-503.

PMID:
25368251
18.

Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.

Karavasilis V, Kosmidis P, Syrigos KN, Mavropoulou P, Dimopoulos MA, Kotoula V, Pectasides D, Boukovinas I, Klouvas G, Kalogera-Fountzila A, Papandreou CN, Fountzilas G, Briasoulis E.

Anticancer Res. 2014 Oct;34(10):5649-55.

PMID:
25275069
19.

Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.

Koumarianou A, Tzeveleki I, Mekras D, Eleftheraki AG, Bobos M, Wirtz R, Fountzilas E, Valavanis C, Xanthakis I, Kalogeras KT, Basdanis G, Pentheroudakis G, Kotoula V, Fountzilas G.

Anticancer Res. 2014 Sep;34(9):4949-62.

PMID:
25202077
20.

Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).

Kotoula V, Bobos M, Vassilakopoulou M, Tsolaki E, Chrisafi S, Psyrri A, Lazaridis G, Papadopoulou K, Efstratiou I, Michail-Strantzia C, Debelenko LV, Kosmidis P, Fountzilas G.

Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):60-70. doi: 10.1097/PAI.0000000000000028.

PMID:
25153496
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk